Medvi vs Shed: Comparing Two Compounded GLP-1 Programs

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to a PlexusDx Education Hub comparison. Our library covers GLP-1 medicine, weight-management protocols, and the genetic signals underneath them. Open the Peptides & GLP-1 collection.

Full head-to-head: PlexusDx vs MEDVi →

This is independent editorial coverage. PlexusDx has no commercial relationship with Medvi or Shed, receives no referral income, and includes no affiliate links.

Medvi and Shed are easy to confuse on paper, because both run the same basic play: telehealth access to a compounding pharmacy for GLP-1 therapy. When two programs share a model, the useful questions shift from "which is different" to "how do I judge either one." That is the angle here — structure, oversight, and the metabolic factor neither program is built to read. Snapshot is April 2026.

When two programs run the same model

Because Medvi and Shed both pair virtual care with compounded semaglutide or tirzepatide, headline features tend to look interchangeable. The meaningful distinctions live in the details: clinician type, pharmacy licensing, follow-up support, and how each handles dose changes. Those are the things worth comparing rather than surface branding or which name you have seen more often.

How Medvi is set up

Medvi (Medvi Wellness) operates as telehealth backed by a compounding-pharmacy pathway. A program of this shape typically starts with a virtual evaluation, moves to a provider-issued prescription, and dispenses through a 503A compounding pharmacy where a compounded product applies. Confirm the current structure on Medvi's official website.

How Shed is set up

Shed follows the same telehealth-plus-compounded-pharmacy template. Its medication menu, tier pricing, and clinical touchpoints are defined on Shed's own website, and — as with any program in this space — those specifics can change between the time this was written and the time you read it, so verify them at the source.

Reading a compounded-pharmacy program critically

For any 503A-based service, a few signals matter more than marketing: are prescribers licensed in your state, is the compounding pharmacy properly registered, is there a real clinical evaluation before a prescription, and is pricing shown plainly. Applying that checklist to both Medvi and Shed is more useful than asking which brand simply sounds more established.

The evidence sits with the compound, not the brand

Both programs dispense the same drug class, and that class carries the clinical record. Semaglutide was studied for weight management in the STEP program (NEJM, 2021); tirzepatide in SURMOUNT (NEJM, 2022); and tirzepatide for obstructive sleep apnea in SURMOUNT-OSA (NEJM, 2024). Endpoints and populations differ across trials, and individual results vary — but the science travels with the molecule.

The metabolic baseline neither program maps

What Medvi and Shed both leave untouched is the inherited biology beneath your GLP-1 response. GLP1R codes for the receptor these compounds bind; a common FTO variant shapes appetite and fat-mass regulation; and TCF7L2 feeds into glucose control and GLP-1 secretion. The PlexusDx Precision Peptide Genetic Test surveys 14 pathways, 49 peptides, 150+ genetic insights spanning that map — without claiming to predict your reaction to any single drug.

The PlexusDx starting point

PlexusDx runs its own Weight Management Protocols with semaglutide and tirzepatide, and pairs them with the Precision Peptide Genetic Test ($298). Rather than choosing a program blind, you can begin with your pathway data and bring it into the clinical conversation — the test-before-you-invest sequence that compounded-only telehealth does not offer.

No affiliation: PlexusDx is unaffiliated with Medvi and Shed and has no commercial arrangement with either.

Keep reading on PlexusDx: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, and GLP 1 What Is.

Editorial note: the above is educational and independent. PlexusDx has no relationship with Medvi or Shed and offers semaglutide and tirzepatide through its own protocols. The Precision Peptide Genetic Test looks at how your genes shape peptide-related pathways and does not predict medication response. Consult a qualified provider before beginning any peptide protocol.

Frequently Asked Questions

How can I tell if Medvi or Shed is legitimate?

Look for state-licensed prescribers, a registered 503A compounding pharmacy, a genuine clinical evaluation before any prescription, and clearly posted pricing. Both Medvi and Shed present these details on their own sites; confirming them there is more reliable than judging a program by its marketing or online reviews alone.

Are Medvi and Shed essentially the same?

They share a model — telehealth plus compounded GLP-1 dispensing — but differ in provider type, pharmacy partner, follow-up cadence, and pricing tiers. Because the drug class is identical, those operational details, not the medication itself, are what actually separate one program from the other in practice.

What is a 503A compounding pharmacy?

A 503A pharmacy prepares medications for individual patients based on a prescription, rather than manufacturing at large scale. Compounded semaglutide and tirzepatide from programs like Medvi and Shed are dispensed through this pathway, which is distinct from the FDA-approved branded products sold at retail pharmacies.

Does genetic testing replace choosing a program?

No. The Precision Peptide Genetic Test does not select a telehealth service or predict drug response. It maps pathway-level variants like FTO so you understand your metabolic baseline before enrolling anywhere — information that stays useful regardless of which program you eventually use.

Part of the PlexusDx Education Hub. See more Peptides & GLP-1 guides.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.